Performance vs S&P 500

03
Tracked Q1 2025–Q2 2026 +352.3%
S&P 500 total return (same window) +37.0%
Excess return +315.3%

Annualized: +234.7% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 99.0% · Options excluded: 0.0%

Sector breakdown

04
Healthcare 100.0%

Full portfolio 3 positions

05
Type Streak 8Q trend
RAPP Rapport Therapeutics, Inc. - Common Stock $261,709,477 52.53% 6,280,525 $38,448,036 Down ×1
SEPN Septerna, Inc. - Common Stock $208,160,143 41.78% 6,215,591 $58,799,491
MAZE Maze Therapeutics, Inc. - Common Stock $28,371,872 5.69% 950,800 $-9,508

Top movers (QoQ)

10
SecurityActionShares ΔValue Δ
SEPN Price move only +0 +$58.8M
RAPP Trimmed -855K +$38.4M
MAZE Price move only +0 -$10K

Exited positions

11

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarterShares beforeValue beforePrice since exit
CRGX Sept. 30, 2025 1,737,216 $7,157,330 No longer tracked